Breast cancer, one of the leading causes of death in women in the United States, challenges therapeutic success in patients due to tumor heterogeneity, treatment resistance, metastasis and disease recurrence. Knowledge of immune system involvement in normal breast development and breast cancer has led...
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, which had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal ti...
Virotherapy, a strategy to use live viruses as therapeutics, is a relatively novel field in the treatment of cancer. With the advancements in molecular biology and virology, there has been a huge increase in research on cancer virotherapy. For the treatm
Two immunotherapy agents have been approved by the Food and Drug Administration for this subtype of breast cancer: atezolizumab (PD-L1 inhibitor) and pembrolizumab (PD-1 inhibitor), in combination with chemotherapy. To receive immunotherapy at this time, the patient's cancer tissue must express PD...
CAR T cells home in on bone marrow and other organs that make up the lymphatic system. But for solid tumors, such as breast cancer, that is usually not the case. Even if they do migrate to the tumor, they don’t persist and expand well there due to the nature of the microenvironment...
Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly target
Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with ...
Breast cancer, the most frequent female malignancy, is often curable when detected at an early stage. The treatment of metastatic breast cancer is more challenging and may be unresponsive to conventional therapy. Immunotherapy is crucial for treating met
The convening of the 3rd International Workshop on Monoclonal Antibodies and Breast Cancer had the character of a self-search exercise. After almost a decade of research in the basic and applied aspects of the use of serological means to diagnose and possibly treat breast cancer several milestones...
& Dy, G. Advances in cancer immunotherapy in solid tumors. Cancers (Basel). 8, (1–21 (2016). Google Scholar Williams, A. D. et al. Immunotherapy for breast cancer: current and future strategies. Curr. Surg. Rep. 5, 31 (2017). PubMed PubMed Central Google Scholar Brown, C. ...